Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q1 2016 Earnings Presentation
7 slides from Anika Therapeutics's earnings presentation, Apr 28, 2016
Slide 1: Anika Therapeutics First Quarter 2016 Earnings Call Presentation
ANIKA THERAPEUTICS, INC. First Quarter 2016 Earnings Call Presentation April 28, 2016
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT The statements made in this presentation that are not statements of historical fact are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements involve known a
Slide 3: Pillars of Growth for Anika
PILLARS OF GROWTH FOR ANIKA Expanding Advancing Globally Pipeline Strengthening Strategic Infrastructure M&A 3
Slide 4: Advancing Growth Strategy
ADVANCING GROWTH STRATEGY Expanding Globally • Received CE Mark approval for CINGAL; Commercial launches in coming months • CINGAL commercial launch in Canada targeted for May 2016 • Engaged new commercial partner in China to market CINGAL and MONOVISC • MONOVISC product registrations underway in In
Slide 5: Advancing Growth Strategy
ADVANCING GROWTH STRATEGY Strengthening Infrastructure • Integration of manufacturing operations is on track; Equipment transfer complete • Commenced construction on new European headquarters in Padua, Italy • Appointed new Chief Medical Officer and Chief Operations Officer Strategic M&A • Pursuing
Slide 6: Strong Financial Foundation
STRONG FINANCIAL FOUNDATION Q1 Q1 FY 2014 FY 2015 2015 2016 Total Revenue $15.5 $22.3 $105.6 $93.0 Net Income $3.5 $6.9 $38.3 $30.8 Diluted EPS $0.23 $0.45 $2.51 $2.01 Dollars in millions, except per-share amounts • Total revenue increased 44% year-over-year in Q1 2016 • Orthobiologics revenue grew
Slide 7: Q&A
Q&A Anika Therapeutics, Inc. First Quarter 2016 Earnings Call Presentation April 28, 2016